

# INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

## MEETING MINUTES

**Meeting Date:** Monday, June 12, 2023  
**Time:** 3:00 pm Eastern Time  
**Web Participants:** <https://us06web.zoom.us/j/82018417857?pwd=Yi9qVzcwclplNUJlZnlHbkZ4cE9Edz09>  
**Telephone Only Participants:** 1-888-788-0099 Access Code: 820 1841 7857  
**Institution:** Children's Healthcare of Atlanta, Inc., Atlanta, GA  
**Principal Investigator:** **Suhag H. Parikh, MD**  
**Protocol:** Sangamo Therapeutics, Inc., **003SCD101**  
**Meeting Type:** Continuing Review of Protocol and Site  
**Title:** A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Sickle Cell Disease

### 1. Call to order:

The Meeting was called to order at 3:19 pm Eastern Time.

### 2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

### 3. Declaration of quorum:

Three voting members were present, including one local member unaffiliated with the institution. Also present were two Institutional Representatives and IBC Services staff. The Chair declared that a quorum was present.

### 4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

### 5. Public posting:

The Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

### 6. Approval of previous meeting minutes:

Minutes Approved - YES: 3 NO: 0 ABSTAIN: 0

### 7. Review of proposed research:

The Chair provided an overview of the dosing status.

The Chair provided an overview of the protocol.

The Chair provided an overview of changes since the last review.

### 8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-2 containment facilities and practices are required for BIVV003**, since it consists of primary human cells modified via mRNA transfection. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of BIVV003 locally**, provided that other biosafety criteria for study closure are also met. The Committee reaffirmed this determination.

## INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

### **9. Vote on the Protocol:**

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 3                      NO: 0                      ABSTAIN: 0

### **10. Review of proposed facilities and practices:**

The Chair provided an overview of the arrangement for the facilities and practices.

#### **Points of Discussion:**

1. The Committee discussed the efficacy of disinfecting agents, including PDI Sani-Cloth AF3 wipes and CaviWipes, and determined that both are effective against the study agent.
2. The Chair noted that Virex II solution is also listed as a disinfecting agent, and an Institutional Representative will follow up with IBC Services on whether or not it is used for work surfaces. The Committee recommended that site documents be updated accordingly upon receipt of the follow-up information.
3. The Committee recommended that typos in the site map be revised.
4. The Committee recommended that site documents be revised to indicate which protocols require a Biological Safety Cabinet as well as which protocols use the different dosing rooms.
5. An Institutional Representative confirmed that disposable eyewash bottles are transported on a mobile cart into rooms without a plumbed eyewash. The Committee recommended that site documents be revised accordingly to reflect this.
6. The Committee recommended that the expiration dates of the disposable eyewash bottles be provided to IBC Services.

### **11. Site requirements:**

The Chair reviewed training and communication requirements for maintaining IBC approval with the Institutional Representatives.

### **12. Vote on the Site:**

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 3                      NO: 0                      ABSTAIN: 0

### **13. Advice to the Institution:** None.

**14. Meeting adjourned:** The meeting was adjourned at 3:23 pm Eastern Time.

### **15. Post-meeting notes:** None.

#### **Documents reviewed:**

Agenda  
Protocol, Amendment 5, dated 08-01-2022  
Investigator's Brochure, Edition 5, dated 07-27-2022  
Cell Therapy Manual, Version 3.0, dated 11-24-2020  
Research Modification Evaluation, Protocol Amendment 5  
Research Modification Evaluation, Investigator's Brochure, Edition 5  
Biological Risk Assessment and Summary, updated 03-23-2023  
Site Maps, updated 05-10-2023  
Site Inspection Checklist, dated 05-10-2023  
Photos, dated 05-10-2023  
Biohazard Sign, dated 10-12-2021

## INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

Biological Safety Cabinet Certification, expires 08-2023  
SOP, Biosafety for BIVV003, dated 06-29-2022  
Training, Shipping Certifications, expire 2024, 2025  
Continuing Review Report Form, dated 03-21-2023  
Prior Meeting Minutes, Continuing, dated 06-06-2022